PMID: 16529163Mar 15, 2006Paper

Identification of factors predicting early evolution of secondary oral hypoglycaemic agent failure and evaluation of clinical standards applied by primary care physicians during qualification to insulin therapy of patients with type 2 diabetes

Annales Academiae Medicae Stetinensis
Michał Machoy

Abstract

Effective control of metabolic disturbances, in particular hyperglycaemia, hypertension and lipid abnormalities, is a prerequisite condition for clinically important reduction in the risk of death related to diabetes and its complications. It appears that type 2 diabetes is a progressive disease and hyperglycaemia aggravates with time. Secondary failure of oral hypoglycaemic agents is a common evolution of long-standing type 2 diabetes and placement on insulin is necessary when maximal sulfonylurea therapy is inadequate. This study was designed to identify factors predicting early hyperglycaemia progression and evolution of secondary oral hypoglycaemic agent (OHA) failure, estimate the prevalence of metabolic disturbances associated with type 2 diabetes and evaluate clinical practices of family physicians during qualification to insulin therapy. Medical records of 56 diabetic patients, 24 males and 32 females with a mean age of 65 years (42-91 yrs), were analyzed. Information about fasting plasma glucose and lipid levels, blood pressure, body mass, kidney status, coronary artery disease and other complications, and treatment were retrospectively extracted from patient charts. All patients were treated by their family physicians...Continue Reading

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.